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Abstract
Background: Tissue factor (TF) and its inhibitor tissue factor pathway inhibitor (TFPI) are the main regulators of the 
initiation of the coagulation process, important in atherothrombosis. In this study we have investigated the frequency 
of six known TF and TFPI single nucleotide polymorphisms (SNPs) in CHD patients as compared to healthy individuals. 
These genotypes and the phenotypes (TF, TFPI free and total antigen) were evaluated with special reference to gender 
and diabetes in the CHD population.
Methods: Patients with angiographically verified CHD (n = 1001; 22% women, 20% diabetics), and 204 healthy controls 
(28% women), were included. The investigated SNPs were: TF -1812C/T and TF -603A/G in the 5'upstream region, TF 
5466A/G in intron 2, TFPI -399C/T and TFPI -287T/C in the 5'upstream region and the TFPI -33T/C in intron 7.
Results: No significant differences in frequencies between the CHD population and the controls of any polymorphisms 
were observed. In the CHD population, the TF 5466 A/G SNP were significantly more frequent in women as compared 
to men (p < 0.001). The TF-1812C/T and the TF-603A/G SNPs were significantly more frequent in women without type-
2 diabetes compared to those with diabetes (p < 0.018, both), and the heterozygous genotypes were associated with 
significantly lower TF plasma levels compared to the homozygous genotypes (p < 0.02, both).
The TFPI-399C/T and the TFPI-33T/C SNPs were associated with lower and higher TFPI total antigen levels,
respectively (p < 0.001, both).
Conclusion: Genetic variations in the TF and TFPI genes seem to be associated with gender and type-2 diabetes, partly 
affecting their respective phenotypes.
Background
Tissue factor (TF) and its endogenous inhibitor, tissue
factor pathway inhibitor (TFPI) are the main regulators of
the initiation of the coagulation process, important in
atherothrombosis. Injury of the vessel wall and rupture of
an atherosclerotic plaque lead to exposure of TF to circu-
lating blood, followed by an activation of the haemostatic
system. In addition, blood-borne, or soluble TF (TF) from
micro particles and monocytes may represent thrombo-
genic potential [1]. TFPI is the main regulator in the ini-
tial step of the coagulation cascade mediated by TF, by
binding to coagulation factors Xa, VIIa and TF forming
an inactive complex [2,3]. TFPI, mainly produced by the
endothelium [4], is predominantly associated with lipo-
proteins in the blood [2,5] or is endothelial-bound [6],
whereas a small portion circulates as free molecules.
Enhanced TF expression has been found in atheroscle-
rotic plaques [7], in which TFPI has been found to co-
localize [8].
Elevated levels of TF has been associated to cardiovas-
cular disease (CVD) [9-11] and also shown to be predic-
tive for future events in some studies [12,13], whereas the
role of TFPI in atherothrombosis remains unclear. How-
ever, a positive correlation between plasma levels of TF
and TFPI in ischemic heart disease has been demon-
strated [9].
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The association between CVD and type-2 diabetes mel-
litus (T2DM) is well established. It has also been shown,
that women with coronary heart disease (CHD) more
often present T2DM than men [14,15], however, the
cause and molecular mechanism underlying this relation-
ship is not fully explored. The atherosclerotic process
includes both environmental and multiple genetic fac-
tors, leading to the unfavorable state in the cardiovascular
system. The accelerated atherosclerosis seen in diabetic
patients might be a consequence of chronic hyperglyce-
mia [16]. Permanent hyperglycemia may lead to glycosy-
lation of proteins, including albumin, and the latter has
been shown to increase the expression of TF in mono-
cytes [17]. Further, elevated levels of circulating TF-pro-
coagulant activity have been demonstrated in patients
with T2DM [18]. Hyperglycemia may also lead to dys-
functional endothelium in which TFPI, suggested to be a
marker of endothelial dysfunction, may be affected [19].
Both genetic and environmental risk factors are able to
modify the expression of proteins, and several genetic
variants in the TF and TFPI gene have been investigated
in relation to CHD [20-26]. Single nucleotide polymor-
phisms (SNPs) may affect the levels of their gene encod-
ing products, leading to a modified susceptibility to CHD.
In the present study we aimed to investigate the fre-
quency of six known SNPs in the genes coding for TF and
TFPI in patients with CHD, as compared to healthy indi-
viduals, and furthermore to explore the influence of these
SNPs on plasma levels of the proteins, with special
emphasis on diabetes and gender differences in a CHD
population. The choice of the investigated polymor-
phisms is based on previous research in the field.
The results of the present study indicate differences in
frequencies of the TF polymorphisms as related to diabe-
tes and gender, and additionally changes in plasma levels
according to the different TF and TFPI SNPs.
Methods
Study population
We studied 1001 patients enrolled in the Aspirin non-
responsiveness and clopidogrel clinical endpoint trial
(ASCET) [27]. All patients had angiographically verified
stable CHD and 97% were Caucasians. The mean age was
62 years and 22% were women. Twenty percent had
T2DM, defined as known T2DM or fasting glucose > 7
mmol/l, 44% had experienced an acute myocardial infarc-
tion (MI). The control group consisted of 204 apparently
healthy controls, mean age 55 years, 28% being women,
all Caucasians. They were included after clinical exami-
nation and an ECG-test, to rule out any clinical evidence
for atherosclerotic disease. The study was approved by
the Regional Ethics Committee and all patients gave their
written informed consent to participate. The ASCET
study is registered at the website; clinicaltrials.gov, with
the identification number: NCT00222261
Blood sampling
Venous blood was collected by standard venipuncture
between 8 and 10 a.m. in fasting condition and without
intake of any medication. Citrated plasma (0.129 M in
dilution 1:10), stored on ice, was separated within 30
minutes by centrifugation at 4°C and 3.000 × g for 20
minutes. For genotype determination, also performed in
the healthy controls, whole blood collected in EDTA
tubes was used. All samples were stored at -80°C until
analyzed. Serum lipids, glucose and HbA1c, were deter-
mined by conventional routine methods.
DNA isolation
DNA was purified from whole blood (EDTA) on the
Magna Pure LC Instrument (Roche Diagnostics GmbH,
Mannheim, Germany), using MagNA Pure DNA LC iso-
lation kit, Large Volume (Roche Diagnostics GmbH). The
DNA Large Volume Blood Protocol of the MagNA Pure
software program, version 3.0, was used for extraction
with settings for an initial sample volume of 500 μl and an
elution volume of 100 μl. DNA purity and quantity were
tested on the NanoDrop, ND-1000 (Saveen Werner, Swe-
den) and DNA was kept at -80°C until analyzed.
Genotype analysis
The TF -1812C/T (rs 958587) and TF -603A/G (rs
1361600) in the 5'upstream region, TF 5466A/G
(rs3917643) in intron 2, the TFPI -399C/T (rs 10153820)
and TFPI -287T/C (rs 10931292) in the 5'upstream
region, and the TFPI -33T/C (rs 8176592) in intron 7
polymorphisms were investigated. Further, the haplotype
TF I (TF -1812CC combined with TF 5466 AA/AG) was
investigated. Allelic discrimination was performed by the
Applied Biosystems 7900HT Fast Real-Time PCR system,
using allele specific primers and probes included in the
Taqman SNP Genotyping assay (TaqMan MGB probes;
FAM and VIC dye-labeled) and the TaqMan Genotyping
Master Mix, (Applied Biosystems, Foster City, CA, USA).
A final reaction volume of 25 μl was used and 1-20 ng of
genomic DNA was added. The Thermal Cycler Condi-
tions were the same for all polymorphisms with an initial
step of 10 min at 95°C followed by 47 cycles of 15 sec at
92°C and 1 min at 60°C each.
Plasma TF and TFPI analyses
Levels of TF and TFPI were measured using commercial
ELISA kits; the Imubind TF kit, recognising TF-apo, TF
and TF-VII complexes (American Diagnostic Inc., Green-
wich, CT, USA), and the Asserachrom TFPI free antigen
and Asserachrom TFPI total antigen kits, recognising the
full-length TFPI molecules, and the full-length and trun-Opstad et al. Thrombosis Journal 2010, 8:7
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cated TFPI molecules including TFPI bound to lipopro-
teins, respectively (Stago Diagnostica, Asnière, France).
The inter-assay coefficients of variation in our laboratory
were 7.9%, 5.6% and 3.8%, respectively.
Statistical analysis
The x2 test was used to test for deviation of the genotype
distribution from Hardy-Weinberg equilibrium. Allele
frequencies were evaluated by gene counting and group
differences for each polymorphism were examined by chi
x2  test. Student t-test or Mann-Whitney test and
Kruskall-Wallis test, when appropriate, were used for
comparing TF and TFPI levels between two or more
groups. Two-tailed probability values of 0.05 or less were
considered statistically significant. Exact p-values are
given, except when p < 0.001 or p > 0.2. All statistical




Baseline characteristics of the included CHD patients are
shown in Table 1. All patients were optimally treated,
thus, 100% were on aspirin and 98% on statin treatment.
Blood samples for genotyping in the CHD group was
detectable in 996 samples. For phenotype analysis, only
performed in the CHD population, measurements of TF
were complete in 983 individuals and of TFPI in 1000.
Genotype distribution and allelic frequencies
The distribution of the TF and TFPI SNPs in CHD
patients and healthy controls is shown in Table 2. All
SNPs conformed to the Hardy-Weinberg equilibrium.
The two TF polymorphisms at positions -1812 and -603
were found to be completely concordant in 1199 of the
total of 1200 individuals. No significant case-control dif-
ferences in frequencies of any TF polymorphisms were
observed, also not when analyzing for the TF I haplotype.
When analyzing the three variants of the TF -1812 and
the TF -603 SNP's separately, the results were similar.
Also for the TFPI SNPs no differences in frequencies
between CHD and healthy controls were found.
In the CHD population, the differences in genotype dis-
tribution between gender and in patients with T2DM or
not, are shown in Table 3. The TF 5466 polymorphism
was significantly more frequent in women, as compared
to men (OR 2.23, 95% CI 1.48-3.37, p < 0.001), and this
was also true when analyzing for the TF I haplotype (OR
2.56 95% CI 1.52-4.31, p < 0.001). The TF -1812 and the
TF -603 polymorphisms were less, but not significantly,
abundant in women (p = 0.124 and 0.115, respectively).
The TFPI -399 polymorphism was more common in
women (p = 0.075). No difference in frequencies was seen
for any genotype between patients presenting with
T2DM or not, or between patients who had previously
experienced MI or not (data not shown).
Due to gender differences, we evaluated the T2DM
genotype distribution in the subgroup of women (n =
218) (Table 4). The TF -1812 and the TF -603 polymor-
phisms were significantly less frequent in CHD women
with T2DM as compared to women without (OR 0.45,
95% CI 0.14-0.88, p = 0.018 for both). These associations
were not observed in men (data not shown).
Plasma levels of TF and TFPI according to genotypes and 
disease state and gender
To evaluate the influence of the investigated SNPs on the
TF and TFPI plasma levels, the biomarkers were mea-
sured in the total CHD population (Table 5). Patients pre-
senting with the TF -1812 and TF -603 polymorphisms
showed significant differences in the TF levels, with the
heterozygous (n = 466) having the lowest levels (p = 0.013
and 0.019, respectively). The TFPI -399 and the TFPI -33
polymorphisms were associated with significantly lower
and higher TFPI total antigen levels, respectively (p <
0.001 for both).
Table 1: Characteristics of the CHD population (n = 1001).
Age (years, mean (range)) 62 (36-81)
Men/Women (%) 783/218 (78/22)
Diabetes Mellitus n (%) 200 (20)
Myocardial infarction n (%) 436 (44)
Hypertension n (%) 553 (56)
SBP (mmHg) 139.4 (19.3)
DBP (mmHg) 82.1 (9.7)
Current smokers n (%) 204 (20.4)
BMI (kg/m2) 27.9 (11.5)
Total cholesterol (mmol/l) 4.6 (1.0)
HDL cholesterol (mmol/l) 1.3 (0.4)
LDL cholesterol (mmol/l) 2.5 (0.8)
Triglycerides (mmol/l) 1.6 (1.1)
Fasting glucose (mmol/l) 6.0 (1.9)







Values are mean (SD) or number (proportions) if not otherwise 
stated.
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; ACE:
angiotensin converting enzyme.Opstad et al. Thrombosis Journal 2010, 8:7
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Table 2: Frequency of the TF and TFPI polymorphisms in CHD patients and healthy controls
Genotype CHD n (%) Controls n (%) p
TF -1812 996 204
CC 327 (32.8) 63 (30.9)
CT 466 (46.8) 102 (50.0) >0.2
TT 203 (20.4) 39 (19.1)
Allele T frequency 0.438 0.441
TF -603 996 204
AA 326 (32.7) 63 (30.9)
AG 466 (46.8) 102 (50.0) > 0.2
GG 204 (20.5) 39 (19.1)
Allele G frequency 0.439 0.441
TF 5466 996 204
AA 879 (88.3) 181 (88.7)
AG 112 (11.3) 22 ) (10.8 > 0.2
GG 5 (0,5) 1 (0.5)
Allele G frequency 0.061 0.059
TFPI-399 996 204
CC 758 (76.1) 158 (77.5)
CT 224 (22.5) 41 (20.1) > 0.2
TT 14 (1.4) 5 (2.5)
Allele T frequency 0.127 0.125
TFPI -287 996 204
TT 723 (72.6) 148 (72.6)
TC 245 (24.6) 55 (27.0) > 0.2
CC 28 (2.8) 1 (0.5)
Allele C frequency 0.151 0.140
TFPI -33 996 203*
TT 512 (51.4) 102 (50.3)
TC 405 (40.7) 87 (42.9) > 0.2
CC 79 (7.9) 14 (6.9)
Allele C frequency 0.283 0.283
Haplotypes
TF I 65 (6.5) 13 (6.4) > 0.2
Calculations are performed with comparison of the heterozygous and homozygous pooled,
versus the wild type.
Haplotypes: TFI is the combination of TF -1812 CC and TF 5466 AG/GG
p-values refer to differences between CHD patients and controls.
*The TFPI -33 polymorphism was detectable in 203 out of 204 controls.Opstad et al. Thrombosis Journal 2010, 8:7
http://www.thrombosisjournal.com/content/8/1/7
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No differences according to the presence of T2DM or
gender were observed (Additional file 1). The patients
who had previously experienced MI (n = 436) had signifi-
cantly higher TFPI total antigen levels as compared to the
subjects without MI (p = 0.008).
Based on the gender differences in genotypes, we fur-
ther analyzed for phenotype in women alone according to
disease state (Additional file 2). TFPI total antigen levels
were lower in females with T2DM (n = 46) as compared
to those without (p = 0.093). When analyzing specifically
for the different genotypes, the TFPI levels in T2DM
women bearing the major allele of TFPI -399 and TFPI -
287 were significantly lower compared to women without
T2DM (p < 0.05 for both) (Figure 1). TFPI free antigen
levels were significantly higher in females previously suf-
fering MI (n = 71) as compared to non-MI women (p =
0.013) (Additional file 2), mainly observed in those bear-
ing the minor allele of the TFPI -399 and the TFPI -33
polymorphisms, and in subjects homozygous for the
major TFPI -287 allele (Figure 1). In men, the TFPI total
antigen was significantly higher in MI patients, irrespec-
tive of genotype (p = 0.025) (data not shown).
Discussion
In this study we could show that the investigated genetic
variants of the TF and the TFPI genes were not differently
distributed between CHD patients and healthy controls.
It seems therefore that these polymorphisms alone not
necessarily dispose for the disease. They might, neverthe-
less, contribute to an increased susceptibility. As CHD
Table 3: Association between TF and TFPI polymorphisms in subgroups of the CHD population
Genotype No with 
T2DM+/-




CC 71/256 22 246/81 25
CT 93/373 20 >0.2 366/100 21 0.124
TT 35/168 17 166/37 18
TF -603
AA 71/255 22 245/81 25
AG 93/373 20 >0.2 366/100 21 0.115
GG 35/169 17 167/37 18
TF 5466
AA 179/700 20 703/176 20
AG 19/93 17 >0.2 72/40 36 <0.001
GG 1/4 20 3/2 40
TFPI -399
CC 151/607 20 602/156 21
CT 45/179 20 >0.2 166/58 26 0.075
TT 3/11 21 10/4 29
TFPI -287
TT 145/578 20 564/159 22
TC 49/196 20 >0.2 194/51 21 >0.2
CC 5/23 18 20/8 29
TFPI -33
TT 97/415 19 399/113 22
TC 87/318 22 >0.2 315/90 22 >0.2
CC 15/64 19 64/15 19
Haplotypes
TF I 13/35 20 >0.2 39/26 40 <0.001
Calculations are performed with comparison of the heterozygous and homozygous pooled, versus the wild type.
Haplotypes: TFI is the combination of TF -1812 CC and TF 5466 AG/GG
p-values refer to differences between disease states and gender, as related to genotype.Opstad et al. Thrombosis Journal 2010, 8:7
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and arterial thrombosis are multifactorial disorders,
including both genetic and environmental factors, we
explored further if these genetic variants were linked to
gender, T2DM and subtypes of CHD (MI).
Frequencies in the CHD population and controls
The observed frequencies of the SNPs in the CHD popu-
lation and healthy controls are mainly in line with other
reports [20-26], also investigating CHD in Caucasians. In
a  S w e d i s h  s t u d y ,  i n  p a t i e n t s  w i t h  a c u t e  c o r o n a r y  s y n -
drome, the TF 5466A/G polymorphism was associated
with cardiovascular death, and the CG haplotype, by TF -
1812C/T and TF 5466 A/G, was associated with a 3-fold
increased risk of death [22]. In our study no association
between any of the investigated polymorphisms and the
presence of stable CHD was observed. It should be noted
that the unbalanced number of cases and controls might
have influenced the results and the control group was
also seven years younger.
We could also not find any association in the subgroup
of CHD patients with previous MI. As for the TF-603 A/
G polymorphism and the association to cardiovascular
events, diverging results are reported [20,21,23]. No case-
Table 4: Frequencies of TF and TFPI polymorphisms in women with CHD according to T2DM or not
Genotype T2DM+ (46) n(%) T2DM- (172) n(%) p
TF -1812
CC 24 (52.2) 57 (33.1) 0.018
CT 17 (37.0) 83 (48.3)
TT 5 (10.9) 32 (18.6)
Allele T frequency 0.294 0.428
TF -603
AA 24 (52.2) 57 (33.1) 0.018
AG 17 (37.0) 83 (48.3)
GG 5 (10.9) 32 (18.6)
Allele G frequency 0.294 0.428
TF 5466
AA 36 (78.3) 140 (81.4) >0.2
AG 9 (19.6) 31 (18.0)
GG 1 (2.2) 1 (0.6)
Allele G frequency 0.120 0.096
TFPI -399
CC 37 (80.4) 119 (69.2) 0.133
CT 9 (19.6) 49 (28.5)
TT 0 4 (2.3)
Allele T frequency 0.098 0.166
TFPI -287
TT 34 (73.9) 125 (72.7) >0.2
TC 9 (19.6) 42 (24.4)
CC 3 (6.5) 5 (2.9)
Allele C frequency 0.163 0.151
TFPI -33
TT 24 (52.2) 89 (51.7) >0.2
TC 21 (45.7) 69 (40.1)
CC 1 (2.2) 14 (8.1)
Allele C frequency 0.251 0.282
Calculations are performed with comparison for the heterozygous and homozygous pooled, versus the wild type.
p-values refer to differences between diabetes versus non-diabetes.Opstad et al. Thrombosis Journal 2010, 8:7
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control differences in frequencies with regard to CHD
have been observed for the TFPI polymorphisms [24,25].
Genotypes and phenotypes in the total CHD population
In our CHD population the heterozygotes for the two
linked TF polymorphisms, the TF-1812C/T and the TF-
603A/G, presented with significantly lower TF plasma
l ev e ls  as  c om pa r ed t o t he  t w o ho mo zy g ous ge no types,
pointing to a potential protecting role of these polymor-
phisms. This is somewhat in contrast to the findings from
smaller sub-sets in the ECTIM and PATHROS studies
[20]. These results were, however, obtained in healthy
individuals. We observed no genotype-phenotype associ-
ation for the TF 5466 SNP, which is in line with the main
results from Mälarstig et al. [22]. They could, however,
show that the TF mRNA expression was influenced by
the SNP. In our study, the TFPI -399C/T and the TFPI -33
T/C polymorphisms were associated with lower and
higher TFPI total antigen levels, respectively, in line with
other reports [25,26]. Thus, both protective and harmful
role of the single nucleotide polymorphisms might be
present. The TFPI -287T/C did not affect the TFPI
plasma levels significantly.
Genotypes and phenotypes as related to gender
The higher prevalence of the TF 5466A/G polymorphism
in women with CHD has previously not been reported
neither the tendency towards a higher prevalence in
women for the TFPI -399C/T polymorphism. As the
TFPI -399C/T SNP seems to lead to lower levels of TFPI,
as shown in our study, and the TF 5466A/G SNP seems to
give higher mRNA levels, shown in another study [22], a
possible prothrombotic state with a combined genotype
in women with CHD might be suggested.
Table 5: Plasma TF and TFPI levels according to genotypes in the total CHD population
Genotypes TF pg/ml* p
TF -1812
CC 150 (107,210)




AG 139 (97,187) 0.019†
GG 153 (109,203)
TF 5466
AA 143 (104, 197)
AG/GG|| 154 (104, 197) >0.2
Free TFPI ng/ml‡ Total TFPI ng/ml‡ p
TFPI -399
CC 15.5 (4.6) 68.6 (14.1)
CT/TT|| 15.1 (5.8) > 0.2 64.2 (14.9) <0.001§
TFPI -287
TT 15.2 (4.9) 67.2 (14.7)
TC/CC|| 15.7 (4.9) 0.178 68.6 (13.6) 0.183
TFPI -33
TT 15.5 (5.2) 63.3 (13.3)
TC/CC|| 15.3 (4.6) > 0.2 72.1 (14.1) <0.001§
* Values are median levels (25 and 75 percentiles)
† Kruskall-Wallis test
‡ Values are mean levels (SD)
§Independent sample t-test
|| Heterozygous and homozygous are combined, due to low number of minor allele homozygous.
p-values refer to differences between genotypes.Opstad et al. Thrombosis Journal 2010, 8:7
http://www.thrombosisjournal.com/content/8/1/7
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Genotypes and phenotypes in women with T2DM
The T and G allele of the TF -1812C/T and the TF -603A/
G polymorphisms, respectively, were significantly more
f r e q u e n t  i n  w o m e n  w i t h o u t  T 2 D M  a s  c o m p a r e d  t o
women with diabetes. As the heterozygous state was
associated with significantly lower TF levels, women with
CHD not presenting with diabetes may be less susceptible
to thrombotic events, and a possible causal role of these
genetic polymorphisms in the pathogenesis of athero-
thrombosis in T2DM may be considered. Patients pre-
senting with diabetes have been shown to be more
hypercoagulable and prone to acute coronary events,
partly through the activation of the TF pathway [28]. As
hyperglycemia and hyperinsulinemia is common in
patients with T2DM, we propose that the recently shown
contribution to the procoagulant state [18], may partly be
TF genotype dependent.
The observed lower TFPI total antigen in the present
study in women with diabetes was only significant for the
TFPI -399 CC and the TFPI -287 TT genotypes, which
my indicate that the regulation of TFPI by hyperglycemia
to some degree is related to the TFPI genotype. However
it should be emphasized that the less frequent genotypes
also may play a role.
Genotypes and phenotypes in women with MI
The frequencies for all SNPs were similar for women with
and without previous MI and plasma levels of TF did not
differ between the groups. Higher TFPI free antigen lev-
els were observed for this group, especially in individuals
bearing the TFPI -399 CT/TT, the TFPI -287 TT and the
TFPI -33TC/CC genotypes. This association was not
observed in men (data not shown). The importance of
TFPI in atherothrombotic disease is still controversial.
Higher plasma levels of TFPI, which have been reported
in CHD patients [9], may reflect a compensatory mecha-
nism due to activation of the TF coagulation pathway, but
may also reflect endothelial dysfunction in the athero-
sclerotic process. The free pool of TFPI includes the full-
length TFPI and generally reflects the changes in
endothelial cell-associated TFPI [29], whereas the free
form with its strong anticoagulant activity is thought to
be important for the function of TFPI in vivo [30]. It may
thus be suggested that women are more prone to develop
a dysfunctional endothelium. Whether this gender dis-
crepancy in plasma levels of TFPI may be important for
the disease progression remains to be elucidated and
require further investigation. Notable, as almost all
patients were on statin treatment no corrections for cho-
Figure 1 Plasma levels of TFPI in women according to genotypes, T2DM and MI. Levels of TFPI total antigen according to genotypes and T2DM 
(n = 46) in upper panel. Levels of TFPI free antigen according to genotypes and MI (n = 71) in lower panel. Values are mean, with error bars representing 
SD.
Figure 1Opstad et al. Thrombosis Journal 2010, 8:7
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lesterol, of possible importance for the measurements of
TFPI total antigen, have been performed.
Conclusion
Genetic variations of the TF and TFPI genes seem to be
associated with gender in the present population of CHD
patients. Women presenting with T2DM showed a differ-
ent pattern in TF and TFPI genotypes, as compared to
women without diabetes, partly related to their respec-
tive phenotypes. The phenotype differences observed are
minor and within the normal range. However, recent
studies have shown that minor increase and decrease in
prothrombotic factors and inhibitors, respectively, may
induce thrombin generation and subsequent thrombus
formation. Thus, a possible enlargement of a TF/TFPI
ratio due to genetic variants, may contribute to a hyper-
coagulable state in CHD, which may be more important
for clinical events in women with diabetes. It should,
however, be underlined that these results have to be con-
firmed in studies more specifically designed, due to low
number in the different subgroups.
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